160
Participants
Start Date
October 12, 2021
Primary Completion Date
June 6, 2022
Study Completion Date
June 6, 2022
LY3526318
Administered orally.
Placebo
Administered orally.
Altoona Center For Clinical Research, Duncansville
Synexus Clinical Research US, Inc - Orlando, The Villages
Synexus Clinical Research US, Inc - Orlando, Orlando
Suncoast Research Group, Miami
New Horizon Research Center, Miami
VIN-Julie Schwartzbard, Aventura
Synexus Clinical Research US, Inc., Pinellas Park
Renstar Medical Research, Ocala
Synexus - Cincinnati, Cincinnati
META Medical Research Institute, Dayton
Great Lakes Research Group, Inc., Bay City
Synexus Clinical Research US, Inc., Chicago
Northwestern University, Chicago
StudyMetrix Research, City of Saint Peters
Clinvest Research LLC, Springfield
Synexus - US, San Antonio
Rocky Mountain Clinical Research, Idaho Falls
Synexus- Chandler, Chandler
Alliance for Multispecialty Research, LLC Tempe, Tempe
Synexus Clinical Research - Glendale, Glendale
Artemis Institute for Clinical Research, San Diego
Artemis Institute for Clinical Research, Riverside
Northwest Clinical Research Center, Bellevue
Rainier Clinical Research Center, Renton
CMR of Greater New Haven, Hamden
Boston Clinical Trials, Boston
ActivMed Practices and Research, Methuen
MedVadis Research Corporation, Waltham
Ponce Medical School Foundation Inc., Ponce
Latin Clinical Trial Center, San Juan
Eli Lilly and Company
INDUSTRY